Corrigendum

Brain PET Poster Sessions PP01-M01 to PP02-N07. J Cereb Blood Flow Metab 2019; 39 (1S): 524–608.

In the first publication of the abstract book, authors were missing from the following abstracts. The full list of authors for these abstracts appears below. Program Secretariat for Brain & Brain PET 2019 would like to apologize for this error.

PP01-M01

Y. Nagai¹, N. Miyakawa¹, H. Takuwa¹, Y. Hori¹, K. Oyama¹, B. Ji¹, M. Takahashi¹, XP. Haung², S.T. Slocum², Y. Xiong³, T. Hirabayashi¹, A. Fujimoto¹, K. Mimura¹, J.G. English², J. Liu³, K. Inoue⁴, K. Kumata⁵, C. Seki¹, M. Ono¹, M. Shimojo¹, MR. Zhang⁵, Y. Tomita⁶, T. Suhara¹, M. Takada⁴, M. Higuchi¹, J. Jin³, B.L. Roth² and T. Minamimoto¹

¹Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

²Department Pharmacology, University of North Carolina at Chapel Hill School of Medicine, USA

³Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, USA

⁴Systems Neurosci. Section, Primate Res. Institute, Kyoto University, Japan

⁵Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

⁶Department of Neurology, Keio University School of Medicine, Japan

PP01-N04

M. Vicente-Rodriguez^1,4, N. Singh¹, D. Cash^1,4, M. Veronese¹, C. Simmons^1,4, A.K. Haji-Dheere³, J. Bordoloi³, K. Sanders⁵, R. Awais⁵, E. Arstad⁵, NIMA Consortium, F. Turkheimer^1,4, C.A. Parker^2,4

¹Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

²GlaxoSmithKline, Stevenage, London, United Kingdom

³PET Centre, St Thomas' Hospital, London, United Kingdom

⁴The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA)

⁵Institute of Nuclear Medicine and Department of Chemistry – Radiochemistry, University College London, United Kingdom

PP01-Q01

D. Erritzoe¹, B.R. Godlewska², G. Rizzo³, G.E. Searle³, Y. Lewis³, J. Passchier³, A. Ashok⁴, O. Howes⁴, R.N. Gunn^1,3, D.J. Nutt¹, P. Cowen², G. Knudsen⁵ and E.A. Rabiner^3,4

¹Imperial College, London, UK

²University of Oxford, Oxford, UK

³Invicro, London, UK

⁴King’s College, London, UK

⁵Rigshospitalet and University of Copenhagen, Denmark

PP02-J02

C. Seki¹, K. Tagai^1,2, H. Shimada^1,3, K. Takahata¹, M. Kubota¹, Y. Takado¹, H. Shinotoh^1,4, Y. Kimura¹, M. Ichise¹, M. Okada¹, T. Kikuchi¹, MR. Zhang¹ and M. Higuchi¹

¹National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

²Department of Psychiatry, Jikei University School of Medicine

³Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

⁴Neurology Clinic Chiba, Chiba-shi, Chiba, Japan

PP02-J03

T.G. Lohith¹, C. Sur¹, T. Taylor¹, N. Dupre¹, C. Furtek¹, Y. Wang¹, J. Kost¹, D. Scott², K. Adamczuk², E. Hostetler¹, J. Evelhoch¹, T. Voss¹ and M. Egan¹

¹MRL, Merck & Co., Inc., Kenilworth, NJ, USA

²Bioclinica, Newark, CA, USA

PP02-J06

R. Radhakrishnan¹, P. Worhunsky¹, MQ. Zheng², S. Najafzadeh², JD. Gallezot², B. Planeta², S. Henry², N. Nabulsi², M. Ranganathan¹, P.D. Skosnik¹, D. Cyril D’Souza¹, M.N. Potenza¹, R.E. Carson², Y. Huang² and D. Matuskey^1,2

¹Dept. of Psychiatry, Yale University School of Medicine, USA

²Dept. of Radiology and Biomedical Imaging, Yale University School of Medicine, USA

PP02-K03

J. Debatisse^1,2, O. Eker^3,4, O. Wateau⁵, N. Costes⁶, I. Mérida⁶, M. Verset⁵, A. Oudotte⁴, AC. Lukaszewicz^4,7, JB. Langlois⁶, C. Léon¹, L. Augeul¹, C. Tourvielle⁶, S. Lancelot^4,6, D. Le Bars^4,6, T. Troalen², H. Contamin⁵, TH. Cho^3,4 and E. Canet-Soulas¹

¹Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1 - Lyon, France

²Siemens Healthcare SAS - Saint-Denis, France

³CREATIS, CNRS UMR 5220, INSERM U1206, Université Claude Bernard Lyon 1, INSA Lyon, Université Jean Monnet Saint-Etienne - Lyon, France

⁴Hospices Civils de Lyon - Lyon, France

⁵Cynbiose SAS - Marcy-L'Etoile, France

⁶CERMEP - Imagerie du vivant - Lyon, France

⁷Université Claude Bernard Lyon 1, Pathophysiology of Injury-Induced Immunosuppression, PI3, EA 7426 - Lyon, France

PP02-K07

Q. Qin^1,2, M. Zhang³, P. Huang⁴, W. Liu⁴, H. Meng³, B. Li³, B. Sun⁴, M. Lin⁵, M. Xu^1,2, Z. Wang⁶, R.C. Stevens^1,2 and G.J. Thompson¹

¹iHuman Institute, ShanghaiTech University, China

²School of Life Science and Technology, ShanghaiTech University, China

³Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

⁴Department of Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

⁵MR Collaboration, Siemens Healthcare Ltd., China

⁶Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, China

PP02-L01

M. Shimojo¹, M. Ono¹, H. Takuwa¹, K. Mimura¹, Y. Nagai¹, M. Fujinaga², T. Kikuchi², M. Okada², C. Seki¹, M. Tokunaga¹, J. Maeda¹, Y. Takado¹, M. Takahashi¹, T. Minamihisamatsu¹, MR. Zhang², Y. Tomita³, N. Suzuki³, A. Maximov⁴, T. Suhara¹, T. Minamimoto¹, N. Sahara¹ and M. Higuchi¹

¹Department of Functional Brain Imaging, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

²Department of Radiopharmaceuticals Development, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

³Department of Neurology, Keio University School of Medicine, Tokyo, Japan

⁴Department of Neuroscience, The Scripps Research Institute, La Jolla, USA